By continuing to browse this site you agree to us using cookies as described in About Cookies

Notice:

Wiley Online Library is migrating to a new platform powered by Atypon, the leading provider of scholarly publishing platforms. The new Wiley Online Library will be migrated over the weekend of February 24 & 25 and will be live on February 26, 2018. For more information, please visit our migration page: http://www.wileyactual.com/WOLMigration/

ABSTRACT

Aims To (i) examine the predictors of mortality in a randomized study of methadone versus buprenorphine maintenance treatment; (ii) compare the survival experience of the randomized subject groups; and (iii) describe the causes of death.

Setting Recruitment through three clinics for a randomized trial of buprenorphine versus methadone maintenance.

Participants A total of 405 heroin-dependent (DSM-IV) participants aged 18 years and above who consented to participate in original study.

Measurements Baseline data from original randomized study; dates and causes of death through data linkage with Births, Deaths and Marriages registries; and longitudinal treatment exposure via State health departments. Predictors of mortality examined through survival analysis.

Findings There was an overall mortality rate of 8.84 deaths per 1000 person-years of follow-up and causes of death were comparable with the literature. Increased exposure to episodes of opioid treatment longer than 7 days reduced the risk of mortality; there was no differential mortality among methadone versus buprenorphine participants. More dependent, heavier users of heroin at baseline had a lower risk of death, and also higher exposure to opioid treatment. Older participants randomized to buprenorphine treatment had significantly improved survival. Aboriginal or Torres Strait Islander participants had a higher risk of death.

Conclusions Increased exposure to opioid maintenance treatment reduces the risk of death in opioid-dependent people. There was no differential reduction between buprenorphine and methadone. Previous studies suggesting differential effects may have been affected by biases in patient selection.

16Birgitte Thylstrup, Thomas Clausen, Morten Hesse, Cardiovascular disease among people with drug use disorders, International Journal of Public Health, 2015, 60, 6, 659CrossRef

17Kun-Chia Chang, Tsung-Hsueh Lu, Kuan-Ying Lee, Jing-Shiang Hwang, Ching-Ming Cheng, Jung-Der Wang, Estimation of life expectancy and the expected years of life lost among heroin users in the era of opioid substitution treatment (OST) in Taiwan, Drug and Alcohol Dependence, 2015, 153, 152CrossRef